SLC5A2 and diabetes mellitus: Study showed that SGLT2 inhibitors could raise the hematocrit [18], even in those without diabetes (as seen in DAPA-HF); it is speculated that these agents may promote erythropoiesis via enhanced EPO secretion by the kidney [19].